Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹96 cr of revenue in its latest quarter (Q2 FY27) and kept 12.8% of sales as profit.
“Progressing through decisive actions Our strong recovery in FY25 has been shaped by our firm belief in the power of disciplined execution and clear purpose. It reflects the Focused on decisive mindset we have cultivated – one that opportunities synergises resilience, responsiveness, clarity, We remain focused on and conviction.”
Healthier than 77% of companies in Healthcare, on the 4 of 6 measures we could read for it. Each measure is ranked against the 118–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 42
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: cash quality, growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in JAGSNPHARM?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹96 cr |
| Other Income | ₹2 cr |
| Total Income | ₹99 cr |
| Cost of Materials | ₹5 cr |
| Purchases of Stock-in-Trade | ₹36 cr |
| Inventory Change (±) | ₹42.5 L |
| Employee Benefit Expense | ₹23 cr |
| Finance Costs | ₹29.1 L |
| Depreciation & Amortisation | ₹2 cr |
| Other Expenses | ₹15 cr |
| Total Expenses | ₹82 cr |
| Exceptional Items | ₹-23.5 L |
| Profit before Tax | ₹16 cr |
| Tax Expense | ₹4 cr |
| Net Profit | ₹12 cr |
| Net margin on total income | 12.5% |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limited | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Dr. Reddy's Laboratories Limited | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limited | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Aurobindo Pharma Limited | ₹1,695 | ₹97,502 cr | 23.7 | 10.9% | 11.3% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹4 / share | 4 Sep 2026 |
| Buyback | Buy Back of Shares | 4 May 2026 |
| Dividend | ₹2.5 / share | 12 Sep 2025 |
| Stock split | Stock Split From Rs.5/- to Rs.2/- | 8 Jan 2025 |
| Dividend | ₹5 / share | 6 Sep 2024 |
| Dividend | ₹5 / share | 21 Aug 2023 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.